Tirzepatide 15MG is a 15-milligram format of tirzepatide, a synthetic peptide studied as a dual agonist at the GIP and GLP 1 receptors. It is of interest in metabolic and endocrine research where incretin signaling is examined. Studies have evaluated tirzepatide in preclinical and clinical settings to better understand receptor bias, signaling kinetics, and downstream biomarker changes.

Tirzepatide 20MG is a 20-milligram format of tirzepatide, a synthetic peptide studied as a dual GIP and GLP 1 receptor agonist. Researchers examine tirzepatide in metabolic research, including models related to glycemic regulation, appetite signaling, and energy balance.

Tirzepatide 45MG is a 45-milligram format of tirzepatide, a synthetic peptide analogue engineered from incretin hormone motifs. Researchers study tirzepatide for its potential activity at incretin receptor pathways and for how such signaling may relate to metabolic regulation in preclinical and clinical research contexts.

Tirzepatide 50MG is a 50-milligram format of tirzepatide, a synthetic peptide studied for its dual activity at GIP and GLP 1 receptors. Research has examined tirzepatide in the context of incretin signalling, glucose metabolism pathways, and energy balance regulation. Its sequence incorporates non natural residues and lipidation that are commonly investigated for effects on peptide stability and receptor engagement.